Eosinophilic Asthma

Respiratory
7
Pipeline Programs
3
Companies
8
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

Teva
CINQAIRApproved
reslizumab
Teva
Interleukin-5 Antagonist [EPC]injection2016

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
4 programs
4
1
ReslizumabPhase 3Monoclonal Antibody1 trial
ReslizumabPhase 3Monoclonal Antibody1 trial
ReslizumabPhase 3Monoclonal Antibody1 trial
ReslizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01508936Completed511Est. Aug 2013
NCT01287039Completed489Est. Mar 2014
NCT01285323Completed464Est. Apr 2014
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ICS-LABAPhase 33 trials
Active Trials
NCT06750289Recruiting400Est. Nov 2027
NCT06020014Completed339Est. Oct 2025
NCT04643158Terminated72Est. Jul 2023
AnaptysBio
AnaptysBioSAN DIEGO, CA
1 program
1
EtokimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03469934CompletedEst. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstraZenecaICS-LABA
TevaReslizumab
TevaReslizumab
TevaReslizumab
TevaReslizumab
AstraZenecaICS-LABA
AstraZenecaICS-LABA
AnaptysBioEtokimab

Clinical Trials (8)

Total enrollment: 3,327 patients across 8 trials

NCT06750289AstraZenecaICS-LABA

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Start: Mar 2025Est. completion: Nov 2027400 patients
Phase 3Recruiting
NCT01508936TevaReslizumab

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Start: Feb 2012Est. completion: Aug 2013511 patients
Phase 3Completed
NCT01290887TevaReslizumab

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Start: Jun 2011Est. completion: Jan 20151,052 patients
Phase 3Terminated
NCT01287039TevaReslizumab

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Start: Apr 2011Est. completion: Mar 2014489 patients
Phase 3Completed
NCT01285323TevaReslizumab

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Start: Mar 2011Est. completion: Apr 2014464 patients
Phase 3Completed
NCT06020014AstraZenecaICS-LABA

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Start: Nov 2023Est. completion: Oct 2025339 patients
Phase 2Completed
NCT04643158AstraZenecaICS-LABA

Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids

Start: Mar 2021Est. completion: Jul 202372 patients
Phase 2Terminated
NCT03469934AnaptysBioEtokimab

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

Start: Nov 2017Est. completion: Oct 2018
Phase 2Completed

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,327 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)